With its focus on annualized relapse rate, ADVANCE’s primary end point showed that in year 1 of an annualized relapse rate, the use of Plegridy (peginterferon beta-1a) (every 2 to 4 weeks) greatly reduced this rate. When compared to placebo (n = 500) 0.397, peginterferon beta-1a q4w (n = 500) brought a 28% reduction (0.288), and peginterferon beta-1a q2w (n = 512) brought a 36% reduction (0.256).
At a satellite symposium during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, presenters focused upon the usage of disease-modifying treatments (DMT) in relapsing-remitting multiple sclerosis (RRMS). The presentation echoed the efficacy of using DMT to delay disease progression and to improve quality-of-life in patients with RRMS. More specifically, discussion focused upon newer therapies, natalizumab and peginterferon beta-1a, and traced their respective efficacies.
Dr Giovannoni advocated for the use of natalizumab in the treatment of RRMS. Giovannoni revealed the overall benefit of the therapy in a post-hoc analysis illustrating years of disease-free activity in patients with RRMS, concluding with a staggering 37% natalizumab versus 7% placebo at the 2-year mark. Giovannoni went on to demonstrate that natalizumab can stabilize EDSS scores, especially when used earlier in the disease course, and that it can bring improvements in fatigue, cognition, bladder function, and quality-of-life.
Prof Calabresi then discussed another DMT, peginterferon beta-1a, and the recent phase-3 ADVANCE study that traced its efficacy. According to Calabresi, peginterferon beta-1a continues the benefits of other interferons including producing meaningful results in multiple measures of MS disease activity, and being well-tolerated with a known side effect profile. To demonstrate the efficacy of the therapy, Calabresi pointed to favorable results in the primary endpoint and secondary end points of the ADVANCE study.
With its focus on annualized relapse rate, ADVANCE’s primary end point showed that in year 1 of an annualized relapse rate, the use of peginterferon beta-1a (every 2 to 4 weeks) greatly reduced this rate. When compared to placebo (n = 500) 0.397, peginterferon beta-1a q4w (n = 500) brought a 28% reduction (0.288), and peginterferon beta-1a q2w (n = 512) brought a 36% reduction (0.256).
With
its focus on annualized relapse rate, ADVANCE’s primary end point
showed that in year 1 of an annualized relapse rate, the use of
peginterferon beta-1a (every 2 to 4 weeks) greatly reduced this rate.
When compared to placebo (n = 500) 0.397, peginterferon beta-1a q4w (n =
500) brought a 28% reduction (0.288), and peginterferon beta-1a q2w (n =
512) brought a 36% reduction (0.256).
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Recent-studies-in-the-uses-of-Natalizumab#sthash.WEFPeVVp.dpuf
READ MORE
With
its focus on annualized relapse rate, ADVANCE’s primary end point
showed that in year 1 of an annualized relapse rate, the use of
peginterferon beta-1a (every 2 to 4 weeks) greatly reduced this rate.
When compared to placebo (n = 500) 0.397, peginterferon beta-1a q4w (n =
500) brought a 28% reduction (0.288), and peginterferon beta-1a q2w (n =
512) brought a 36% reduction (0.256).
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Recent-studies-in-the-uses-of-Natalizumab#sthash.WEFPeVVp.dpuf READ MORE
